摘要
视神经脊髓炎谱系病(NMOSD)是严重的致残性中枢神经系统自身免疫性疾病。多为复发型病程,残疾进展呈发作依赖性,预防复发NMOSD的维持治疗是缓解期治疗的关键。2019年起NMOSD维持治疗取得突破性进展,3种靶向药物相继获批适应证。当前维持治疗种类繁多,传统的超适应证和新型药物的适应证并存,尚缺乏对相关研究的总结。文中从传统非特异性免疫抑制剂及特异性靶向药物角度对NMOSD维持治疗药物的疗效性及安全性作综述。
Neuromyelitis optica spectrum disorder(NMOSD) is a severely disabling autoimmune disease of the central nervous system. The course of NMOSD is mostly relapsing, and the progression of disability is related to acute attack. Maintenance treatment is of great important to prevent NMOSD relapse. Since 2019, three specific monoclonal antibodies have been proved for NMOSD, which has enabled great progress in NMOSD treatment. Conventional off-label therapy and newly approved therapy make up a rich variety of maintenance treatment for NMOSD. However, study summarizing conventional and new maintenance treatment in NMOSD is lacking. The current study made a comprehensive summary of the efficacy and safety of maintenance treatment in NMOSD covering traditional non-specific immunosuppressants and specific monoclonal antibodies.
作者
黄文娟
谭红梅
常雪纯
汪亮
张包静子
周磊
赵重波
卢家红
全超
HUANG Wen-juan;TAN Honge-mei;CHANG Xue-chun;WANG Lang;ZHANGBAO Jing-zi;ZHOU Lei;ZHAO Chong-bo;LU Jia-hong;QUAN Chao(Department of Neurology,Huashan Hospital,Fudan University,Shanghai,China)
出处
《中国临床神经科学》
2022年第1期92-100,共9页
Chinese Journal of Clinical Neurosciences
基金
上海市科技重大专项课题(编号:2018SHZDZX01)
科技部国家重点研发计划(编号:2016YFC0901504)
国家自然科学基金(编号:81771296,81801196,82171341)。
关键词
视神经脊髓炎谱系病
水通道蛋白4
维持治疗
neuromyelitis optica spectrum disorder
aquaporin-4
maintenance treatment
